UBS Group
NVCT icon

UBS Group’s Nuvectis Pharma NVCT Stock Holding History

UBS Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$298K Buy
38,563
+30,188
+360% +$259K ﹤0.01% 6410
2025
Q4 		$63.2K Sell
8,375
-17,094
-67% -$111K ﹤0.01% 7114
2025
Q3 		$153K Buy
25,469
+15,211
+148% +$105K ﹤0.01% 6828
2025
Q2 		$76.6K Sell
10,258
-101,262
-91% -$918K ﹤0.01% 7446
2025
Q1 		$1.09M Buy
111,520
+108,851
+4,078% +$784K ﹤0.01% 5216
2024
Q4 		$14.4K Buy
2,669
+2,658
+24,164% +$16.6K ﹤0.01% 8095
2024
Q3 		$69 Sell
11
-2
-15% -$13 ﹤0.01% 9201
2024
Q2 		$82 Sell
13
-7,607
-100% -$51.7K ﹤0.01% 9187
2024
Q1 		$62.5K Sell
7,620
-440
-5% -$3.74K ﹤0.01% 6418
2023
Q4 		$67.2K Buy
8,060
+4,284
+113% +$38.2K ﹤0.01% 6391
2023
Q3 		$48.7K Sell
3,776
-203
-5% -$2.94K ﹤0.01% 6302
2023
Q2 		$63.5K Buy
+3,979
New +$63.5K ﹤0.01% 6331
2022
Q4 		– Sell
-220
Closed -$2K – 11011
2022
Q3 		$2K Buy
220
+158
+255% +$1.47K ﹤0.01% 9750
2022
Q2 		$1K Sell
62
-79
-56% -$977 ﹤0.01% 9922
2022
Q1 		$1K Buy
+141
New +$981 ﹤0.01% 9893

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's NVCT Position: Q1 2026 in Review

UBS Group increased its Nuvectis Pharma (NVCT) stake by 360% in Q1 2026, buying an estimated $259K and bringing the position to 38,563 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #6410.

UBS Group first reported a position in NVCT in Q1 2022 and has held it in 15 quarters since. The position peaked at $1.09M in Q1 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • UBS Group held 38,563 shares of Nuvectis Pharma worth $298K as of Q1 2026.
  • UBS Group bought 30,188 Nuvectis Pharma shares in Q1 2026, an estimated $259K.
  • Nuvectis Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6410 holding.
  • UBS Group first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 15 quarters since.
  • UBS Group's Nuvectis Pharma position peaked at $1.09M in Q1 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.